ondon, Ontario, March 21, 2024: London Research & Pharmaceuticals has recently publicized data about its lead compound LRP-661 or Cannabidiol sulphate (CBDS), highlighting its safety, efficacy, bioavailability, and predictable PK parameters. CBDS maintains improved oral formulation capabilities vs cannabidiol, including tablet and water-based solutions.
When compared against the currently available oral solution of cannabidiol in a sesame oil suspension, CBDS shows no effect on gastrointestinal tolerability (no diarrhea) and no weight loss in animals, as well as no liver or renal toxicity and low affinity for many CYP-450 isozymes (such as 1A2, 3A4, 2B6) or P-glycoprotein (P-GP), which are responsible for many adverse drug-drug interactions.
CBDS demonstrates high activity in several preclinical epilepsy models in which seizures are induced in animals through either the administration of an electrical shock (such as Maximal Electroshock Seizure [MES] and MES Threshold models) or the administration of a seizure-inducing compound, such as pentylenetetrazol (PTZ) in the PTZ–induced seizure mice model.
This data was presented at the prestigious ETDD XVII conference in Miami on June 2nd, 2023, and was well received by the expert audience. It remains widely acknowledged that the clinical utility of cannabidiol is severely limited by the